Dr. Edgar Braendle serves as Chief Medical Officer of AVEO Oncology, an LG Chem company. Dr. Braendle is a life sciences executive bringing over 20 years of experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development.

Dr. Braendle most recently served as Chief Development Officer of Autolus Therapeutics Plc (Autolus), where he was responsible for all development functions and the conduct of a pivotal program in CD-19 directed genetically modified autologous T-cell immunotherapy for adult acute lymphoblastic leukemia, and the respective filing to the U.S. Food & Drug Administration and European Medicines Agency. Prior to his time at Autolus, Dr. Braendle held the role of Executive Vice President, Chief Medical Officer and Global Head of Development at Sumitomo Dainippon Pharma Oncology (Sumitomo), where he was responsible for a full range of development functions and progressed several early-stage, first in human programs and late-stage programs. Prior to his time at Sumitomo, Dr. Braendle served as President and CEO of ARUP Laboratories, a national clinical and anatomic reference laboratory. Dr. Braendle also spent over a decade at Novartis AG, where he served as Senior Vice President and Global Head of Companion Diagnostics and led the company’s precision medicine approach.

Dr. Braendle received his medical degree at RWTH Aachen University in Germany, followed by specialty training in medical oncology, urology and pharmacology. Dr. Braendle is also an associate professor at the University of Ulm, Germany.